Black Diamond Therapeutics (BDTX) Interest Expenses (2018 - 2026)

Black Diamond Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• Quarterly Interest Expenses rose 2.71% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 2.7% YoY) and the FY2025 annual result came in at $124.2 million, down 2.64% from the prior year.
• Interest Expenses was $1.1 million for Q1 2026 at Black Diamond Therapeutics, roughly flat from $1.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $35.7 million in Q3 2022 and bottomed at $584000.0 in Q2 2025.
• A 5-year average of $8.1 million and a median of $1.1 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses soared 324.23% — and 2025, when it plunged 97.93%.
• Black Diamond Therapeutics' Interest Expenses stood at $1.1 million in 2022, then rose by 2.76% to $1.1 million in 2023, then advanced by 2.69% to $1.1 million in 2024, then advanced by 2.71% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
• Business Quant data shows BDTX's Interest Expenses at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $5.5 million in Q3 2025.